Creative Planning Makes New $59,000 Investment in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)

Creative Planning purchased a new stake in shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 15,686 shares of the specialty pharmaceutical company’s stock, valued at approximately $59,000. Creative Planning owned 0.12% of Eagle Pharmaceuticals at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in EGRX. Headlands Technologies LLC raised its holdings in Eagle Pharmaceuticals by 75.7% in the first quarter. Headlands Technologies LLC now owns 6,641 shares of the specialty pharmaceutical company’s stock worth $35,000 after purchasing an additional 2,861 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Eagle Pharmaceuticals by 0.4% during the first quarter. Vanguard Group Inc. now owns 640,754 shares of the specialty pharmaceutical company’s stock valued at $3,358,000 after acquiring an additional 2,630 shares in the last quarter. Price T Rowe Associates Inc. MD purchased a new position in Eagle Pharmaceuticals in the 1st quarter worth approximately $83,000. AIGH Capital Management LLC lifted its position in Eagle Pharmaceuticals by 2.1% in the 2nd quarter. AIGH Capital Management LLC now owns 1,211,509 shares of the specialty pharmaceutical company’s stock valued at $6,784,000 after acquiring an additional 25,000 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC bought a new position in Eagle Pharmaceuticals in the 2nd quarter valued at approximately $76,000. Institutional investors own 85.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on Eagle Pharmaceuticals in a report on Wednesday. They issued a “hold” rating on the stock.

Eagle Pharmaceuticals Price Performance

Shares of NASDAQ EGRX opened at $0.90 on Wednesday. The firm has a fifty day moving average price of $2.09 and a 200-day moving average price of $3.74. Eagle Pharmaceuticals, Inc. has a 1 year low of $0.00 and a 1 year high of $9.89.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.